{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:44:13Z","timestamp":1776091453773,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA195563"],"award-info":[{"award-number":["R01CA195563"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018488","name":"Clinical and Translational Science Institute, University of Florida","doi-asserted-by":"publisher","award":["UL1 TR001427"],"award-info":[{"award-number":["UL1 TR001427"]}],"id":[{"id":"10.13039\/100018488","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Adam Rosen Research Foundation"},{"name":"Cure Group 4 Medulloblastoma Consortium"},{"name":"Lillian S. Wells Foundation"},{"name":"National Pediatric Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The current standard of care treatments for medulloblastoma are insufficient as these do not take tumor heterogeneity into account. Newer, safer, patient-specific treatment approaches are required to treat high-risk medulloblastoma patients who are not cured by the standard therapies. Immunotherapy is a promising treatment modality that could be key to improving survival and avoiding morbidity. For an effective immune response, appropriate tumor antigens must be targeted. While medulloblastoma patients with subgroup-specific genetic substitutions have been previously reported, the immunogenicity of these genetic alterations remains unknown. The aim of this study is to identify potential tumor rejection antigens for the development of antigen-directed cellular therapies for medulloblastoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed a cancer immunogenomics pipeline and performed a comprehensive analysis of medulloblastoma subgroup-specific transcription profiles (<jats:italic>n<\/jats:italic>\u2009=\u2009170, 18 WNT, 46 SHH, 41 Group 3, and 65 Group 4 patient tumors) available through International Cancer Genome Consortium (ICGC) and European Genome-Phenome Archive (EGA). We performed in silico antigen prediction across a broad array of antigen classes including neoantigens, tumor-associated antigens (TAAs), and fusion proteins. Furthermore, we evaluated the antigen processing and presentation pathway in tumor cells and the immune infiltrating cell landscape using the latest computational deconvolution methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Medulloblastoma patients were found to express multiple private and shared immunogenic antigens. The proportion of predicted TAAs was higher than neoantigens and gene fusions for all molecular subgroups, except for sonic hedgehog (SHH), which had a higher neoantigen burden. Importantly, cancer-testis antigens, as well as previously unappreciated neurodevelopmental antigens, were found to be expressed by most patients across all medulloblastoma subgroups. Despite being immunologically cold, medulloblastoma subgroups were found to have distinct immune cell gene signatures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using a custom antigen prediction pipeline, we identified potential tumor rejection antigens with important implications for the development of immunotherapy for medulloblastoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13073-024-01363-y","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T10:02:57Z","timestamp":1724061777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Changlin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrunda","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongjun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate M.","family":"Candelario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Yegorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-213X","authenticated-orcid":false,"given":"Duane A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"6","key":"1363_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","journal-title":"Acta Neuropathol"},{"issue":"suppl_4","key":"1363_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol. 2018;20(suppl_4):iv1\u201386. https:\/\/doi.org\/10.1093\/neuonc\/noy131.","journal-title":"Neuro Oncol"},{"issue":"7767","key":"1363_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41586-019-1158-7","volume":"572","author":"MC Vladoiu","year":"2019","unstructured":"Vladoiu MC, El-Hamamy I, Donovan LK, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019;572(7767):67\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1158-7.","journal-title":"Nature"},{"issue":"4","key":"1363_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11864-014-0306-4","volume":"15","author":"AM Martin","year":"2014","unstructured":"Martin AM, Raabe E, Eberhart C, Cohen KJ. Management of pediatric and adult patients with medulloblastoma. Curr Treat Options Oncol. 2014;15(4):581\u201394. https:\/\/doi.org\/10.1007\/s11864-014-0306-4.","journal-title":"Curr Treat Options Oncol"},{"issue":"34","key":"1363_CR5","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","volume":"34","author":"AO von Bueren","year":"2016","unstructured":"von Bueren AO, Kortmann RD, von Hoff K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016;34(34):4151\u201360. https:\/\/doi.org\/10.1200\/JCO.2016.67.2428.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1363_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","volume":"7","author":"A Gajjar","year":"2006","unstructured":"Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(06)70867-1.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1363_CR7","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1200\/JCO.2011.40.2792","volume":"30","author":"RI Jakacki","year":"2012","unstructured":"Jakacki RI, Burger PC, Zhou T, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children\u2019s Oncology Group Phase I\/II study. J Clin Oncol. 2012;30(21):2648\u201353. https:\/\/doi.org\/10.1200\/JCO.2011.40.2792.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1363_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00381-017-3548-1","volume":"33","author":"L Veneroni","year":"2017","unstructured":"Veneroni L, Boschetti L, Barretta F, et al. Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy. Childs Nerv Syst. 2017;33(11):1969\u201376. https:\/\/doi.org\/10.1007\/s00381-017-3548-1.","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"1363_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3171\/2019.5.PEDS18381","volume":"24","author":"K Juraschka","year":"2019","unstructured":"Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr. 2019;24(4):353\u201363. https:\/\/doi.org\/10.3171\/2019.5.PEDS18381.","journal-title":"J Neurosurg Pediatr"},{"issue":"8","key":"1363_CR10","doi-asserted-by":"publisher","first-page":"e3088","DOI":"10.1371\/journal.pone.0003088","volume":"3","author":"M Kool","year":"2008","unstructured":"Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8):e3088. https:\/\/doi.org\/10.1371\/journal.pone.0003088.","journal-title":"PLoS One"},{"issue":"11","key":"1363_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","volume":"29","author":"PA Northcott","year":"2011","unstructured":"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408\u201314. https:\/\/doi.org\/10.1200\/JCO.2009.27.4324.","journal-title":"J Clin Oncol"},{"issue":"7663","key":"1363_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature22973","volume":"547","author":"PA Northcott","year":"2017","unstructured":"Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311\u20137. https:\/\/doi.org\/10.1038\/nature22973.","journal-title":"Nature"},{"issue":"7510","key":"1363_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13379","volume":"511","author":"PA Northcott","year":"2014","unstructured":"Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511(7510):428\u201334. https:\/\/doi.org\/10.1038\/nature13379.","journal-title":"Nature"},{"issue":"1","key":"1363_CR14","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1038\/s41467-021-26936-y","volume":"12","author":"S Rivero-Hinojosa","year":"2021","unstructured":"Rivero-Hinojosa S, Grant M, Panigrahi A, et al. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors. Nat Commun. 2021;12(1):6689. https:\/\/doi.org\/10.1038\/s41467-021-26936-y.","journal-title":"Nat Commun"},{"issue":"7","key":"1363_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","volume":"18","author":"EC Schwalbe","year":"2017","unstructured":"Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017;18(7):958\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30243-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1363_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737-754.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.005.","journal-title":"Cancer Cell"},{"issue":"11","key":"1363_CR17","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/cam4.1171","volume":"6","author":"F Bautista","year":"2017","unstructured":"Bautista F, Fioravantti V, de Rojas T, et al. Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Med. 2017;6(11):2606\u201324. https:\/\/doi.org\/10.1002\/cam4.1171.","journal-title":"Cancer Med"},{"issue":"4","key":"1363_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","volume":"20","author":"P Bandopadhayay","year":"2014","unstructured":"Bandopadhayay P, Bergthold G, Nguyen B, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20(4):912\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2281.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1363_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","volume":"29","author":"Y Pei","year":"2016","unstructured":"Pei Y, Liu KW, Wang J, et al. HDAC and PI3K Antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell. 2016;29(3):311\u201323. https:\/\/doi.org\/10.1016\/j.ccell.2016.02.011.","journal-title":"Cancer Cell"},{"issue":"24","key":"1363_CR20","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33(24):2646\u201354. https:\/\/doi.org\/10.1200\/JCO.2014.60.1591.","journal-title":"J Clin Oncol"},{"key":"1363_CR21","doi-asserted-by":"publisher","unstructured":"Purzner T, Purzner J, Buckstaff T, et al. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Sci Signal. 2018;11(547)\nhttps:\/\/doi.org\/10.1126\/scisignal.aau5147.","DOI":"10.1126\/scisignal.aau5147"},{"issue":"1","key":"1363_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","volume":"3","author":"EI Hwang","year":"2022","unstructured":"Hwang EI, Sayour EJ, Flores CT, et al. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022;3(1):11\u201324. https:\/\/doi.org\/10.1038\/s43018-021-00319-0.","journal-title":"Nat Cancer"},{"issue":"3","key":"1363_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1078-0432.CCR-15-0713","volume":"22","author":"CD Pham","year":"2016","unstructured":"Pham CD, Flores C, Yang C, et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin Cancer Res. 2016;22(3):582\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0713.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1363_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454\u201372. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.013.","journal-title":"Cancer Cell"},{"issue":"10","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen SP, Loffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020;17(10):595\u2013610. https:\/\/doi.org\/10.1038\/s41571-020-0387-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6230","key":"1363_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"issue":"1","key":"1363_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","volume":"27","author":"RF Wang","year":"2017","unstructured":"Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017;27(1):11\u201337. https:\/\/doi.org\/10.1038\/cr.2016.155.","journal-title":"Cell Res"},{"key":"1363_CR28","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","volume":"8","author":"M Efremova","year":"2017","unstructured":"Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679. https:\/\/doi.org\/10.3389\/fimmu.2017.01679.","journal-title":"Front Immunol"},{"issue":"5","key":"1363_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1101\/gr.165985.113","volume":"24","author":"SD Brown","year":"2014","unstructured":"Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(5):743\u201350. https:\/\/doi.org\/10.1101\/gr.165985.113.","journal-title":"Genome Res"},{"issue":"9","key":"1363_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nbt.3932","volume":"35","author":"A Vitiello","year":"2017","unstructured":"Vitiello A, Zanetti M. Neoantigen prediction and the need for validation. Nat Biotechnol. 2017;35(9):815\u20137. https:\/\/doi.org\/10.1038\/nbt.3932.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1363_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/bioinformatics\/btab759","volume":"38","author":"D Rieder","year":"2022","unstructured":"Rieder D, Fotakis G, Ausserhofer M, et al. nextNEOpi: a comprehensive pipeline for computational neoantigen prediction. Bioinformatics. 2022;38(4):1131\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btab759.","journal-title":"Bioinformatics"},{"issue":"1","key":"1363_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12859-019-2876-4","volume":"20","author":"RO Schenck","year":"2019","unstructured":"Schenck RO, Lakatos E, Gatenbee C, et al. NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline. BMC Bioinformatics. 2019;20(1):264. https:\/\/doi.org\/10.1186\/s12859-019-2876-4.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"1363_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830.e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"issue":"1","key":"1363_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13073-017-0468-3","volume":"9","author":"TC Chang","year":"2017","unstructured":"Chang TC, Carter RA, Li Y, et al. The neoepitope landscape in pediatric cancers. Genome Med. 2017;9(1):78. https:\/\/doi.org\/10.1186\/s13073-017-0468-3.","journal-title":"Genome Med"},{"key":"1363_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-024-01281-z","volume":"16","author":"V Trivedi","year":"2024","unstructured":"Trivedi V, Yang C, Klippel K, et al. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. Genome Med. 2024;16:17. https:\/\/doi.org\/10.1186\/s13073-024-01281-z.","journal-title":"Genome Med"},{"issue":"7793","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Consortium ITP-CAoWG","year":"2020","unstructured":"Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6.","journal-title":"Nature"},{"issue":"7803","key":"1363_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-020-2164-5","volume":"580","author":"SM Waszak","year":"2020","unstructured":"Waszak SM, Robinson GW, Gudenas BL, et al. Germline elongator mutations in sonic hedgehog medulloblastoma. Nature. 2020;580(7803):396. https:\/\/doi.org\/10.1038\/s41586-020-2164-5.","journal-title":"Nature"},{"key":"1363_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2105-9-11","volume":"9","author":"A Doring","year":"2008","unstructured":"Doring A, Weese D, Rausch T, Reinert K. SeqAn an efficient, generic C++ library for sequence analysis. BMC Bioinformatics. 2008;9:11. https:\/\/doi.org\/10.1186\/1471-2105-9-11.","journal-title":"BMC Bioinformatics"},{"issue":"23","key":"1363_CR39","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btu548.","journal-title":"Bioinformatics"},{"key":"1363_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/1471-2164-15-325","volume":"15","author":"Y Bai","year":"2014","unstructured":"Bai Y, Ni M, Cooper B, Wei F, Fury W. Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads. BMC Genomics. 2014;15:325. https:\/\/doi.org\/10.1186\/1471-2164-15-325.","journal-title":"BMC Genomics"},{"key":"1363_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. https:\/\/doi.org\/10.1186\/1471-2105-12-323.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"1363_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314\u20136. https:\/\/doi.org\/10.1038\/nbt.3772.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1363_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4.","journal-title":"Genome Biol"},{"issue":"1","key":"1363_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal J, Carreno BM, Petti AA, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11. https:\/\/doi.org\/10.1186\/s13073-016-0264-5.","journal-title":"Genome Med"},{"issue":"3","key":"1363_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal J, Kiwala S, McMichael J, et al. pVACtools: A Computational Toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. 2020;8(3):409\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0401.","journal-title":"Cancer Immunol Res"},{"key":"1363_CR46","doi-asserted-by":"publisher","unstructured":"Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20(1):213. https:\/\/doi.org\/10.1186\/s13059-019-1842-9.","DOI":"10.1186\/s13059-019-1842-9"},{"key":"1363_CR47","doi-asserted-by":"publisher","unstructured":"Charlie Murphy OE. AGFusion: annotate and visualize gene fusions. BioRxiv. 2016. https:\/\/doi.org\/10.1101\/080903.","DOI":"10.1101\/080903"},{"key":"1363_CR48","doi-asserted-by":"publisher","unstructured":"Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize Implements and enhances circular visualization in R. Bioinformatics. 2014;30(19):2811\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btu393.","DOI":"10.1093\/bioinformatics\/btu393"},{"issue":"16","key":"1363_CR49","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btp352.","journal-title":"Bioinformatics"},{"issue":"21","key":"1363_CR50","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1093\/bioinformatics\/btr509","volume":"27","author":"H Li","year":"2011","unstructured":"Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27(21):2987\u201393. https:\/\/doi.org\/10.1093\/bioinformatics\/btr509.","journal-title":"Bioinformatics"},{"key":"1363_CR51","unstructured":"Yang C, Trivedi V et al. Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma. Dropbox raw counts\/data https:\/\/www.dropbox.com\/scl\/fi\/oz2shf2glyiqx09qc6sy6\/manuscript_0922.RData?rlkey=yne2c17aslieeu6ox5k696uek&dl=0."},{"issue":"7767","key":"1363_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41586-019-1434-6","volume":"572","author":"V Hovestadt","year":"2019","unstructured":"Hovestadt V, Smith KS, Bihannic L, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019;572(7767):74\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1434-6.","journal-title":"Nature"},{"key":"1363_CR53","doi-asserted-by":"publisher","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573\u201387.e29. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"1363_CR54","doi-asserted-by":"publisher","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res. 2020;9\nhttps:\/\/doi.org\/10.12688\/f1000research.24956.2.","DOI":"10.12688\/f1000research.24956.2"},{"key":"1363_CR55","doi-asserted-by":"publisher","first-page":"14049","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng GX, Terry JM, Belgrader P, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. https:\/\/doi.org\/10.1038\/ncomms14049.","journal-title":"Nat Commun"},{"issue":"7","key":"1363_CR56","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382. https:\/\/doi.org\/10.1038\/s41587-019-0114-2.","journal-title":"Nat Biotechnol"},{"issue":"18","key":"1363_CR57","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btw313.","journal-title":"Bioinformatics"},{"key":"1363_CR58","unstructured":"Yang C, Trivedi V et al. Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma. Github R notebook.\u00a0https:\/\/github.com\/Mitchelllab\/Medulloblastoma_Manuscript ."},{"issue":"W1","key":"1363_CR59","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449\u201354. https:\/\/doi.org\/10.1093\/nar\/gkaa379.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"1363_CR60","doi-asserted-by":"publisher","first-page":"eabe3348","DOI":"10.1126\/sciadv.abe3348","volume":"7","author":"A Cachot","year":"2021","unstructured":"Cachot A, Bilous M, Liu YC, et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. 2021;7(9):eabe3348. https:\/\/doi.org\/10.1126\/sciadv.abe3348.","journal-title":"Sci Adv"},{"issue":"4","key":"1363_CR61","first-page":"395","volume":"12","author":"S Ghafouri-Fard","year":"2009","unstructured":"Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med. 2009;12(4):395\u2013404.","journal-title":"Arch Iran Med"},{"issue":"18","key":"1363_CR62","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.18632\/oncotarget.4694","volume":"6","author":"MF Gjerstorff","year":"2015","unstructured":"Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer\/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6(18):15772\u201387. https:\/\/doi.org\/10.18632\/oncotarget.4694.","journal-title":"Oncotarget"},{"issue":"7929","key":"1363_CR63","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41586-022-05208-9","volume":"609","author":"KS Smith","year":"2022","unstructured":"Smith KS, Bihannic L, Gudenas BL, et al. Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature. 2022;609(7929):1012\u201320. https:\/\/doi.org\/10.1038\/s41586-022-05208-9.","journal-title":"Nature"},{"issue":"19","key":"1363_CR64","doi-asserted-by":"publisher","first-page":"28169","DOI":"10.18632\/oncotarget.8612","volume":"7","author":"S Oh","year":"2016","unstructured":"Oh S, Flynn RA, Floor SN, et al. Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. Oncotarget. 2016;7(19):28169\u201382. https:\/\/doi.org\/10.18632\/oncotarget.8612.","journal-title":"Oncotarget"},{"issue":"44","key":"1363_CR65","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1038\/onc.2016.108","volume":"35","author":"X Shi","year":"2016","unstructured":"Shi X, Wang Q, Gu J, et al. SMARCA4\/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development. Oncogene. 2016;35(44):5746\u201358. https:\/\/doi.org\/10.1038\/onc.2016.108.","journal-title":"Oncogene"},{"issue":"1","key":"1363_CR66","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40478-023-01654-2","volume":"11","author":"C G\u00f6bel","year":"2023","unstructured":"G\u00f6bel C, Godbole S, Schoof M, et al. MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice. Acta Neuropathol Commun. 2023;11(1):174. https:\/\/doi.org\/10.1186\/s40478-023-01654-2.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"1363_CR67","doi-asserted-by":"publisher","first-page":"e1398877","DOI":"10.1080\/2162402X.2017.1398877","volume":"7","author":"JF Vermeulen","year":"2017","unstructured":"Vermeulen JF, Van Hecke W, Adriaansen EJM, et al. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. Oncoimmunology. 2017;7(3):e1398877. https:\/\/doi.org\/10.1080\/2162402X.2017.1398877.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1363_CR68","doi-asserted-by":"publisher","first-page":"e1462430","DOI":"10.1080\/2162402X.2018.1462430","volume":"7","author":"M Bockmayr","year":"2018","unstructured":"Bockmayr M, Mohme M, Klauschen F, Winkler B, et al. Subgroup-specific immune and stromal microenvironment in medulloblastoma. Oncoimmunology. 2018;7(9):e1462430. https:\/\/doi.org\/10.1080\/2162402X.2018.1462430.","journal-title":"Oncoimmunology"},{"key":"1363_CR69","doi-asserted-by":"publisher","unstructured":"Riemondy KA, et al. Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. Neuro Oncol 24.2(2022): 273\u2013286. https:\/\/doi.org\/10.1093\/neuonc\/noab135.","DOI":"10.1093\/neuonc\/noab135"},{"issue":"6","key":"1363_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrneurol.2017.64","volume":"13","author":"M Weller","year":"2017","unstructured":"Weller M, Roth P, Preusser M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017;13(6):363\u201374. https:\/\/doi.org\/10.1038\/nrneurol.2017.64.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1363_CR71","doi-asserted-by":"publisher","first-page":"eaav9879","DOI":"10.1126\/sciadv.aav9879","volume":"5","author":"C Flores","year":"2019","unstructured":"Flores C, Wildes T, Dean BD, et al. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Sci Adv. 2019;5(11):eaav9879. https:\/\/doi.org\/10.1126\/sciadv.aav9879.","journal-title":"Sci Adv"},{"issue":"2","key":"1363_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/jcm8020263","volume":"8","author":"R Kikuchi","year":"2019","unstructured":"Kikuchi R, Ueda R, Saito K, et al. A pilot study of vaccine therapy with multiple glioma oncoantigen\/glioma angiogenesis-associated antigen peptides for patients with recurrent\/progressive high-grade glioma. J Clin Med. 2019;8(2):263. https:\/\/doi.org\/10.3390\/jcm8020263.","journal-title":"J Clin Med"},{"issue":"3","key":"1363_CR73","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells DK, van Buuren MM, Dang KK, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818-834.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.09.015.","journal-title":"Cell"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-024-01363-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T10:08:54Z","timestamp":1724062134000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-024-01363-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1186\/s13073-024-01363-y","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data was de-identified and derived from publicly available datasets. No new patient data was presented in this body of work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they do not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}